| 1 |
35414060 | Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage. | 2022 Apr 12 |
1 |
| 2 |
33524223 | Doxorubicin-induced senescence promotes stemness and tumorigenicity in EpCAM-/CD133- nonstem cell population in hepatocellular carcinoma cell line, HuH-7. | 2021 Aug |
1 |
| 3 |
33544209 | Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway. | 2021 May |
2 |
| 4 |
34732441 | Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. | 2021 Nov |
1 |
| 5 |
32096603 | Integrated bioinformatics analysis of the crucial candidate genes and pathways associated with glucocorticoid resistance in acute lymphoblastic leukemia. | 2020 Apr |
1 |
| 6 |
32106373 | MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc. | 2020 May |
4 |
| 7 |
33256379 | Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. | 2020 Dec 1 |
3 |
| 8 |
30834613 | Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization. | 2019 Jul |
1 |
| 9 |
30914792 | Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. | 2019 Oct |
1 |
| 10 |
31132617 | Liposome-coated nano doxorubicin induces apoptosis on oral squamous cell carcinoma CAL-27 cells. | 2019 Jul |
2 |
| 11 |
29185119 | PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer. | 2018 Apr |
1 |
| 12 |
29750424 | Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. | 2018 Jul |
3 |
| 13 |
30020405 | PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression. | 2018 Aug 1 |
1 |
| 14 |
30501868 | Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. | 2018 Dec |
1 |
| 15 |
28232072 | BRG1 and BRM function antagonistically with c-MYC in adult cardiomyocytes to regulate conduction and contractility. | 2017 Apr |
1 |
| 16 |
28291124 | MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway. | 2017 Apr |
1 |
| 17 |
28819559 | Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer. | 2017 Sep |
1 |
| 18 |
28843484 | Cell-Cycle Position of Single MYC-Driven Cancer Cells Dictates Their Susceptibility to a Chemotherapeutic Drug. | 2017 Sep 27 |
1 |
| 19 |
26596829 | Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells. | 2016 May |
3 |
| 20 |
26922833 | Nemorubicin and doxorubicin bind the G-quadruplex sequences of the human telomeres and of the c-MYC promoter element Pu22. | 2016 Jun |
1 |
| 21 |
26927665 | Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. | 2016 Jul 15 |
1 |
| 22 |
27231235 | Farnesiferol c induces apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers. | 2016 May 27 |
1 |
| 23 |
25468432 | Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. | 2015 Jan |
1 |
| 24 |
25835050 | c-Myc modulation: a key role in melanoma drug response. | 2015 |
1 |
| 25 |
25871400 | Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. | 2015 Apr 30 |
1 |
| 26 |
25894737 | Establishment of a porcine pancreatic stem cell line using T-REx(™) system-inducible Wnt3a expression. | 2015 Jun |
1 |
| 27 |
26218671 | Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling. | 2015 Nov 1 |
1 |
| 28 |
26528706 | Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. | 2015 Nov 3 |
3 |
| 29 |
24719189 | MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. | 2014 Jul |
1 |
| 30 |
24840054 | Involvement of HIF-1α activation in the doxorubicin resistance of human osteosarcoma cells. | 2014 Jul |
1 |
| 31 |
23335369 | MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. | 2013 Mar 21 |
1 |
| 32 |
23555992 | Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. | 2013 |
1 |
| 33 |
25073258 | An unusual case of mycosis fungoides with high proliferation index and C-MYC/8q24 translocation. | 2013 Nov-Dec |
1 |
| 34 |
22128783 | Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies. | 2012 Jan 12 |
1 |
| 35 |
22213394 | Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. | 2012 Sep 1 |
1 |
| 36 |
22851565 | Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. | 2012 Oct 1 |
1 |
| 37 |
21575199 | IκB kinases increase Myc protein stability and enhance progression of breast cancer cells. | 2011 May 16 |
1 |
| 38 |
22132187 | Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression. | 2011 |
1 |
| 39 |
20460382 | Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. | 2010 Jul 16 |
1 |
| 40 |
20498406 | Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. | 2010 Jul 10 |
1 |
| 41 |
18166243 | Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. | 2008 Feb 18 |
2 |
| 42 |
16316634 | Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. | 2006 Jan 12 |
3 |
| 43 |
16788862 | Downregulation of the PI3K/Akt survival pathway in cells with deregulated expression of c-Myc. | 2006 Aug |
1 |
| 44 |
14990581 | Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. | 2004 May 14 |
4 |
| 45 |
15153331 | Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. | 2004 May-Jun |
1 |
| 46 |
12736715 | Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level. | 2003 Jun |
1 |
| 47 |
12390804 | [Up-regulation of c-myc expression in MCF-7/Adr human breast cancer cells and its association with resistance against doxorubicin]. | 2002 Feb |
4 |
| 48 |
12435808 | c-Myc exerts a protective function through ornithine decarboxylase against cellular insults. | 2002 Dec |
1 |
| 49 |
11585056 | Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells. | 2001 Sep 1 |
1 |
| 50 |
9625435 | Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine. | 1998 Mar |
2 |